Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations
Source : https://pubmed.ncbi.nlm.nih.gov/38694825/
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for...
CAR-T cell therapy in AML shows promise but faces challenges in target specificity. Ongoing trials and innovations aim to overcome limitations, improving outcomes for relapsed/refractory patients.
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Source : https://pubmed.ncbi.nlm.nih.gov/38378362/
Venetoclax-cobimetinib showed limited preliminary efficacy similar to single-agent venetoclax, but with added toxicity. Our findings will inform future trials of BCL-2/MAPK pathway inhibitor combinations.
Venetoclax-cobimetinib demonstrated limited efficacy with significant toxicity, resembling single-agent venetoclax. Future trials should refine BCL-2/MAPK pathway inhibitor combinations.
Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38610812/
Over the past two decades, the prognosis in adolescents and young adults (AYAs) diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard intensive cytotoxic treatment approach for AYAs...
Venetoclax shows promise as a safe and effective therapy for refractory/relapsed AML in adolescents and young adults, though more research is needed to confirm its benefits in this group.
Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38916714/
For adult patients diagnosed with relapsed B cell-ALL (B-ALL), there have been significant improvements in available treatment options following the FDA approval of novel cellular and immunotherapy approaches - blinatumomab,...
Novel therapies like blinatumomab, CAR T therapy, and inotuzumab improve outcomes in relapsed adult B-ALL, while T-ALL lacks similar advancements, though new therapies are being explored.
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies
Source : https://pubmed.ncbi.nlm.nih.gov/38397092/
Chimeric antigen receptor (CAR)-T-cell therapy has greatly improved outcomes for patients with relapsed or refractory hematological malignancies. However, challenges such as treatment resistance, relapse, and severe toxicity still hinder its...
Single-cell sequencing elucidates the complex transcriptional landscape of leukemia and CAR-T cells, offering insights to overcome clinical challenges, improve CAR-T design, and enhance therapeutic outcomes.